SKYRIZI® Risankizumab-rzaa 150 mg / mL Injection Single-Dose Prefilled Cartridge 2.4 mL

Features

• SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults
• SKYRIZI is indicated for the treatment of moderately to severely active Crohn's disease in adults
• 360 mg/2.4 mL (150 mg/mL) single-dose prefilled cartridge with on-body injector
• Store in a refrigerator at 36°F to 46° F (2°C to 8°C)